Dysregulated protein kinase C (PKC) distribution and activation, and abnormal receptor-G protein coupling, have been implicated in the pathophysiology of bipolar affective disorder (BD). The therapeutic effectiveness of lithium has also been correlated with its ability to reduce PKC activation and G protein-mediated signaling. We examine the cellular distribution and activation of PKC and receptor-G protein coupling in blood platelets from normal controls, patients with BD mania or schizophrenia during treatment-free state, and after lithium or valproic acid administration. PKC activity was measured under basal and 50 nM phorbol 12-myristate, 13-acetate (PMA), 1 microM serotonin or 0.5 U/ml thrombin-stimulated conditions. The coupling of G proteins to serotonin or thrombin receptors were assessed by serotonin or thrombin-mediated [35S]GTPgammaS binding to membrane Galpha proteins. The results demonstrate that membrane-associated PKC activity and stimulus-induced PKC translocation are increased in BD manic, whereas stimulus-elicited PKC translocation is attenuated in schizophrenic patients. Lithium and valproic acid treatments attenuated the stimulus-induced PKC translocations to a similar degree and decreased PKC activity in both cytosolic and membranous fractions after two weeks of drug administration. An increase in 5-HT or thrombin stimulated [35S]GTPgammaS binding to Galpha proteins was detected in BD manic but not in schizophrenic patients although basal [35S]GTPgammaS binding was not different across the diagnostic groups. Lithium and valproic acid treatments similarly reduced receptor-G protein coupling with comparable time courses. Thus, increased membrane-associated PKC, cytosol to membrane PKC translocation and receptor-G protein coupling in platelets of BD manic patients were alleviated by lithium or valproic acid treatments.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jpsychires.2004.10.007 | DOI Listing |
Cancer Epidemiol
January 2025
Vaccine and Drug Evaluation Centre, Department of Community Health Sciences, University of Manitoba, S108-750 Bannatyne Avenue, Winnipeg, MB R3E 0W2, Canada; College of Pharmacy, University of Manitoba, 750 McDermot Avenue, Winnipeg, MB R3E 0T5, Canada.
Background: Little is known on the effect of glycogen synthase kinase-3ß inhibitors (GSK3Is), as a class, on prostate cancer (PC). We aimed to study this in the Canadian province of Manitoba, because mixed results have been reported on the effect of valproate.
Methods: We conducted a nested case-control study among cancer-free Manitobans with ≥ 5 years of medical history in which we matched all men 40 years or older diagnosed with PC between 2000 and 2018 (N = 11,189) on period, age, length of available drug information to cancer-free controls (N = 55,728).
Curr Psychiatry Rep
December 2024
Department of Psychiatry and Behavioral Sciences, Dell Medical School, The University of Texas at Austin, AMG Seton Behavioral Health, 1301 W. 38th Street, Suite 700, Austin, TX, 78757, USA.
Toxicol Res (Camb)
December 2024
Forensic Medicine and Clinical Toxicology Department, Faculty of Medicine, The Medical Campus, 6th Floor, Al-Geish Street, Tanta University, Tanta, Elgharbya 31527, Egypt.
Background: Mood-stabilizer drugs are associated with a considerable incidence of morbidity and mortality.
Aim: This study aimed to assess the pattern, severity, and outcomes of poisoning with acute mood stabilizer drugs among admitted patients to Tanta University Poison Control Center, Egypt between January 2021 and September 2023.
Patients And Methods: This cross-sectional study was conducted in patients with acute mood stabilizer drug poisoning.
ScientificWorldJournal
November 2024
Faculty of Medicine, Universitas Nahdlatul Ulama Surabaya, Bisui General Hospital, South Halmahera, Indonesia.
Currently, there is no gold standard technique in SCI therapy. Although there have been many systematic reviews on the pharmacological treatment of inflammation in SCI, there has been no published discussion regarding the effectiveness of anti-inflammatory pharmacotherapy when viewed from a neuroinflammatory pathway. This research aimed to examine an effective and reliable medication for decreasing inflammation in SCI and, where possible, identify effective pharmacotherapeutic treatment protocols.
View Article and Find Full Text PDFBMJ Open
November 2024
Department of Psychiatry and Behavioural Neurosciences, Hamilton, Stockholm, Sweden.
Objective: This study aims to conduct an overview on the comparative efficacy of valproate in acute mania, bipolar depression and maintenance treatment of bipolar disorder (BD).
Method: We performed an overview of systematic reviews with meta-analyses of randomised controlled trials (RCTs), registered in PROSPERO (CRD42024497749). We searched Medline and Cochrane Database of Systematic Reviews.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!